Cardiovascular Safety Assessment
Cardiovascular safety assessment refers to the evaluation of potential adverse effects of drugs or other interventions on the cardiovascular system. LeadQuest Biotech’s Cardiovascular safety Assessment involves studying cover various aspects of drug effects on the cardiovascular system, including electrophysiological activity, cytotoxicity, myocardial structure, and cardiovascular function, thereby ensuring comprehensive assessment of drug cardiovascular safety. It is an essential component of preclinical and clinical drug development to identify and mitigate any risks of cardiovascular-related adverse events.
Cardiovascular Safety Assessment Services
1.In Vitro hERG Assay
Utilizing FLIPR, Qpatch, and Manual Patch techniques for comprehensive evaluation.
2.Cardiomyocyte/Tissue Action Potential Detection
Utilizing cutting-edge UPLC or LC-MS techniques for precisely assessment of cardiac cellular activity.
3.Cytotoxicity Testing
Employing iPS-CM+ CellTiter-Glo assay2 for thorough cytotoxicity assessment.
4.Multi-Channel Detection
Sequence 1: Evaluation of Cav1.2, Nav1.5, and NaL channels.
Sequence 2: Assessment of Iks, Kv4.3, Kv1.5, and Kir2.1 channels.
5.ECG Detection
Conducting ECG measurements under anesthesia/wakefulness in guinea pigs.
6.Isolated Langendorff Heart
Evaluation of ECG, left ventricular pressure, and coronary flow for comprehensive cardiac assessment.
7.Cardiomyocyte Calcium Activity Assay
FLIPR-based detection for precise assessment of calcium oscillations.
8.Myocardial Structural Toxicity Biomarker Assay
Including cardiac troponins (cTnI), NT-proBNP, and myeloperoxidase for comprehensive evaluation.
9.Shrinkage Detection
Precise assessment of cardiac tissue integrity.
In-House Model for Cardiovascular Safety Assessment
LeadQuest Biotech has developed a range of animal models, encompassing arrhythmia, myocardial ischemia, and heart failure, for an extensive pharmacological evaluation of the cardiovascular system.
1.Heart Failure Models
1)Increased Afterload
- Aortic Constriction
- Salt-Sensitive HF Model
2)Increased Preload
- Arteriovenous Fistula
- Valve Insufficiency Method
- Vena Cava Constriction
3)HF model with Reduced Myocardial Contractility
- Coronary Artery Ischemic Cardiomyopathy
- Rapid Ventricular Pacing
2.Drug Models
Various agents like isoproterenol, doxorubicin, rubidazone, leurosine (vinyltripyrrolidone), sodium pentobarbital, molsidomine, isoprenaline, and ethanol are utilized to induce reduced myocardial contractility in developing HF models.
3.Arrhythmia Models
1)Barium Chloride Model
2)Calcium Chloride Model
3)Chloroform-Induced Arrhythmia Model
4)Cardiac Glycoside Arrhythmia Model
5)Atrial Fibrillation Model
6)Myocardial Ischemia-Reperfusion Arrhythmia
Evaluation Techniques
1.In Vitro/Ex Vivo
- Ion Channel Studies
- Stem Cell-Induced Differentiation of Cardiomyocytes
- Isolated Heart (Langendorff Perfusion)
2.Hemodynamics
- Blood Pressure and Heart Rate Monitoring (Telemetry/JET)
3.Cardiac Contractility
- Direct Effects on Isolated Heart
- Catheterization Studies in Animals
- Non-Invasive Echocardiographic Studies
4.Cardiac Structure and Function Analysis